Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Mar 19, 2014
Insider Transaction Report
Form 4
Chai-Onn Robert Roswell
EVP, GC & Corp. Sec.
Transactions
- Exercise/Conversion
Non-Qualified Stock
2014-03-17−5,000→ 20,203 totalExercise: $6.45From: 2008-08-09Exp: 2014-08-09→ Common Shares, no par value (5,000 underlying) - Exercise/Conversion
Common Stock, no par value
2014-03-17$6.45/sh+5,000$32,250→ 28,999 total - Sale
Common Stock, no par value
2014-03-17$141.72/sh−5,000$708,600→ 23,999 total
Footnotes (3)
- [F1]This number represents options exercised and sold pursuant to a 10b5-1 trading plan.
- [F2]This number represents the weighted average sale price for all sales of common stock sold by the reporting officer pursuant to a 10b5-1 trading plan. Actual sale executions were in the range of $141.63 and $141.80. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
- [F3]The options vested one-fourth per year over four years starting from the date of grant with the first vest date falling on the first anniversary of the grant, the second vest date falling on the second anniversary of the grant, the third vest date falling on the third anniversary of the grant, and the fourth vest date falling fourth anniversary of the grant.